×
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
NASDAQ:INCY

Incyte Stock Forecast, Price & News

$79.25
+1.58 (+2.03%)
(As of 07/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$76.93
$79.29
50-Day Range
$66.18
$80.72
52-Week Range
$61.91
$84.86
Volume
1.45 million shs
Average Volume
1.28 million shs
Market Capitalization
$17.55 billion
P/E Ratio
18.87
Dividend Yield
N/A
Price Target
$87.09

Incyte MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
9.9% Upside
$87.09 Price Target
Short Interest
Bearish
3.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.35
Upright™ Environmental Score
News Sentiment
0.61mentions of Incyte in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$3.67 M Sold Last Quarter
Proj. Earnings Growth
60.17%
From $2.31 to $3.70 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.46 out of 5 stars

Medical Sector

178th out of 1,426 stocks

Commercial Physical Research Industry

4th out of 24 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

Incyte logo

About Incyte (NASDAQ:INCY) Stock

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

INCY Stock News Headlines

Incyte: Growth Drivers Are Coming
See More Headlines

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,094
Year Founded
1991

Company Calendar

Last Earnings
5/03/2022
Today
7/06/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$87.09
High Stock Price Forecast
$109.00
Low Stock Price Forecast
$56.00
Forecasted Upside/Downside
+9.9%
Consensus Rating
Hold
Rating Score (0-4)
2.44444444444444
Research Coverage
9 Analysts

Profitability

Net Income
$948.58 million
Pretax Margin
18.35%

Debt

Sales & Book Value

Annual Sales
$2.99 billion
Cash Flow
$2.43 per share
Book Value
$17.07 per share

Miscellaneous

Free Float
186,507,000
Market Cap
$17.55 billion
Optionable
Optionable
Beta
0.66

Social Links















Incyte Frequently Asked Questions

Should I buy or sell Incyte stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Incyte stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View analyst ratings for Incyte
or view top-rated stocks.

What is Incyte's stock price forecast for 2022?

9 analysts have issued 1 year target prices for Incyte's stock. Their INCY stock forecasts range from $56.00 to $109.00. On average, they expect Incyte's share price to reach $87.09 in the next twelve months. This suggests a possible upside of 9.9% from the stock's current price.
View analysts' price targets for Incyte
or view top-rated stocks among Wall Street analysts.

How has Incyte's stock price performed in 2022?

Incyte's stock was trading at $73.40 on January 1st, 2022. Since then, INCY stock has increased by 8.0% and is now trading at $79.25.
View the best growth stocks for 2022 here
.

When is Incyte's next earnings date?

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Incyte
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) issued its earnings results on Tuesday, May, 3rd. The biopharmaceutical company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. The biopharmaceutical company earned $733.20 million during the quarter, compared to analyst estimates of $753.54 million. Incyte had a trailing twelve-month return on equity of 12.77% and a net margin of 29.95%. The business's quarterly revenue was up 21.3% on a year-over-year basis. During the same quarter last year, the business posted $0.50 earnings per share.
View Incyte's earnings history
.

Who are Incyte's key executives?

Incyte's management team includes the following people:

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte CEO Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among Incyte's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $79.25.

How much money does Incyte make?

Incyte (NASDAQ:INCY) has a market capitalization of $17.55 billion and generates $2.99 billion in revenue each year. The biopharmaceutical company earns $948.58 million in net income (profit) each year or $4.20 on an earnings per share basis.

How many employees does Incyte have?

Incyte employs 2,094 workers across the globe.

When was Incyte founded?

Incyte was founded in 1991.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for Incyte is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750.

This page (NASDAQ:INCY) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.